We Are Crinetics

Crinetics is a pharmaceutical company that develops much-needed therapies for people with rare endocrine diseases. We’re here for patients who are eager to find therapies that provide effective disease control and more simplicity in their lives. We partner with healthcare practitioners to ensure we’re solving real problems for them. And we build value in the company for investors by filling real market needs. Whatever brought you here, welcome.

Watch Our Video

Read the Latest

September 21, 2020

Crinetics Pharmaceuticals Receives Rare Pediatric Disease Designation from FDA for CRN04777 for the Treatment of Congenital Hyperinsulinism

Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today announced that the U.S. Food and Drug Administration (“FDA”) has granted rare pediatric disease designation (“RPD”) for CRN04777, an investigational, orally available, somatostatin receptor type 5 (SST5) agonist being developed as a treatment for congenital hyperinsulinism (HI). Congenital HI is a devastating rare disease in which infants are born with life threatening hypoglycemia (low blood glucose) due to excess insulin secretion.

September 14, 2020

Crinetics Pharmaceuticals Provides New Data From Paltusotine and ACTH Antagonist Development Programs at European Congress of Endocrinology

A presentation on the company’s orally administered, small molecule adrenocorticotropic hormone (ACTH) antagonist was selected for a late-breaking session at the virtual European Congress of Endocrinology (eECE) on September 8, 2020.

Pipeline

We support patients, endocrinologists, and healthcare providers by finding better therapies for rare endocrine diseases and endocrine oncology such as:

Our investigational drug for acromegaly is entering Phase 3. But that’s just at the forefront of the important work we’re doing to combat endocrine disease.
See the science >

Paltusotine (oral SST2 agonist)
Acromegaly
Paltusotine (oral SST2 agonist)
Neuroendocrine Tumors (NETs)
CRN04777 (oral SST5 agonist)
Congenital Hyperinsulinism (congenital HI)
Oral ACTH Antagonist
Cushing's Disease, Congenital Adrenal Hyperplasia (CAH)
Undisclosed Novel Program
Discovery Pre-Clinical Phase 1 Phase 2 Phase 3

Press Releases

Investor Relations

Investor Relations Crinetics Pharmaceuticals

News